## TRACER (S1415CD) NEWSLETTER

## HICOR swog <br> Leading cancer research. Together.

TrACER: A Pragmatic Trial Assessing CSF Prescribing Effectiveness and Risk

October 2017

## STUDY UPDATES

+ As of 10/16/17, we have 970 patients registered across 40 components ( 12 out of 13 Cohort components, 7 out of 8 Usual Care components, 10 out of 12 Intervention Arm 3 components, and 11 out of 12 Intervention Arm 4 components).
+ As of 10/16/17, 22 of our 24 intervention components have completed their order change process and are open for enrollment.


## CONGRATULATIONS AND THANK YOU TO...

The following sites for enrolling their first patient as of 10/16/17:

* William Beaumont Hospital in Troy, MI

ڤ Saint Alphonsus Regional Medical Center in Boise, ID

## Congratulations to Novant Health Forsythe Medical Center for completing $100 \%$ of their enrollment!!

## ELIGIBILITY: ENGLISH AND SPANISH ONLY

TrACER is limited to patients who speak English and/or Spanish because the study's validated patientcompleted forms must be completed in English or Spanish. See Section 5.3b.

## ACCRUAL GOALS

TrACER is reliant on each component meeting its accrual goal by March 31, 2019. If you are facing barriers to reaching your accrual goal (90 eligible patients RCT arm, 56 eligible patients cohort arm), please get in touch with the TrACER team ASAP to help problem solve.

## Contact Us

Site Requirements, including regimen questions: HICOR, TrACER@fredhutch.org; phone: 206-667-7624 Patient eligibility, study procedures, and data submission: SWOG Data Ops: cancercontrolquestion@crab.org; phone: 206-652-2267

